American Journal of Hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. 1085 - 1102
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2016, Volume 91, Issue 10, pp. 1052 - 1055
Journal Article
BLOOD, ISSN 0006-4971, 10/2019, Volume 134, Issue 16, pp. 1275 - 1277
In this issue of Blood, Gao et al demonstrate that extracorporeal photopheresis (ECP), when used as monotherapy in the first-, second-, or third-line therapy...
HEMATOLOGY | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA
HEMATOLOGY | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA
Journal Article
4.
Full Text
Cutaneous B‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management
American Journal of Hematology, ISSN 0361-8609, 10/2016, Volume 91, Issue 10, pp. 1052 - 1055
Disease overview Approximately one‐fourth of cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary...
Immunohistochemistry | Skin Neoplasms - pathology | Risk Assessment | Skin Neoplasms - therapy | Humans | Lymphoma, B-Cell - diagnosis | Lymphoma, B-Cell - therapy | Skin Neoplasms - diagnosis | Lymphoma, B-Cell - pathology | Disease Management | Chemotherapy | Lymphomas | Skin | Diagnosis | Cancer
Immunohistochemistry | Skin Neoplasms - pathology | Risk Assessment | Skin Neoplasms - therapy | Humans | Lymphoma, B-Cell - diagnosis | Lymphoma, B-Cell - therapy | Skin Neoplasms - diagnosis | Lymphoma, B-Cell - pathology | Disease Management | Chemotherapy | Lymphomas | Skin | Diagnosis | Cancer
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2016, Volume 91, Issue 1, pp. 113 - 122
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2016, Volume 91, Issue 1, pp. 151 - 165
Journal Article
7.
Full Text
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management
American Journal of Hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. 1085 - 1102
Disease overview: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the majority of which may be...
PEGYLATED LIPOSOMAL DOXORUBICIN | HISTONE DEACETYLASE INHIBITOR | PHASE-II TRIAL | LOW-DOSE METHOTREXATE | FLOW-CYTOMETRIC ASSESSMENT | PERIPHERAL-BLOOD LYMPHOCYTES | HEMATOLOGY | NF-KAPPA-B | ANTI-CD52 MONOCLONAL-ANTIBODY | PREDICTS SUPERIOR SURVIVAL | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Sezary Syndrome - immunology | Mycosis Fungoides - immunology | Prognosis | Risk Assessment | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Lymphoma, T-Cell, Cutaneous - diagnosis | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Histone Deacetylase Inhibitors - administration & dosage | Lymphoma, T-Cell, Cutaneous - therapy | Stem Cell Transplantation | Sezary Syndrome - diagnosis | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | Skin Neoplasms - diagnosis | Survival Analysis | Histone Deacetylase Inhibitors - therapeutic use | Neoplasm Staging | Histone Deacetylase Inhibitors - adverse effects | Mycosis Fungoides - diagnosis | Chemotherapy | Dermatology | Stem cells | Formulae, receipts, prescriptions | Mycoses | Dermatologic agents | Transplantation | Non-Hodgkin's lymphomas | Diagnosis | T cells | Cancer | Index Medicus
PEGYLATED LIPOSOMAL DOXORUBICIN | HISTONE DEACETYLASE INHIBITOR | PHASE-II TRIAL | LOW-DOSE METHOTREXATE | FLOW-CYTOMETRIC ASSESSMENT | PERIPHERAL-BLOOD LYMPHOCYTES | HEMATOLOGY | NF-KAPPA-B | ANTI-CD52 MONOCLONAL-ANTIBODY | PREDICTS SUPERIOR SURVIVAL | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Sezary Syndrome - immunology | Mycosis Fungoides - immunology | Prognosis | Risk Assessment | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Lymphoma, T-Cell, Cutaneous - diagnosis | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Histone Deacetylase Inhibitors - administration & dosage | Lymphoma, T-Cell, Cutaneous - therapy | Stem Cell Transplantation | Sezary Syndrome - diagnosis | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | Skin Neoplasms - diagnosis | Survival Analysis | Histone Deacetylase Inhibitors - therapeutic use | Neoplasm Staging | Histone Deacetylase Inhibitors - adverse effects | Mycosis Fungoides - diagnosis | Chemotherapy | Dermatology | Stem cells | Formulae, receipts, prescriptions | Mycoses | Dermatologic agents | Transplantation | Non-Hodgkin's lymphomas | Diagnosis | T cells | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2015, Volume 125, Issue 12, pp. 1847 - 1848
In this issue of Blood, Duvic et al demonstrate that mogamulizumab, a humanized monoclonal antibody targeting the chemokine receptor CCR4, is well tolerated...
RECEPTOR 4 ANTIBODY | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA | SEZARY-SYNDROME | HEMATOLOGY | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, CCR4 - immunology | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Female | Lymphoma, T-Cell, Cutaneous - therapy | Male
RECEPTOR 4 ANTIBODY | MYCOSIS-FUNGOIDES | T-CELL LYMPHOMA | SEZARY-SYNDROME | HEMATOLOGY | Antibodies, Monoclonal, Humanized - therapeutic use | Receptors, CCR4 - immunology | Lymphoma, T-Cell, Cutaneous - immunology | Humans | Female | Lymphoma, T-Cell, Cutaneous - therapy | Male
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2015, Volume 90, Issue 1, pp. 73 - 76
Journal Article
10.
Full Text
Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management
American Journal of Hematology, ISSN 0361-8609, 08/2014, Volume 89, Issue 8, pp. 837 - 851
Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be...
PEGYLATED LIPOSOMAL DOXORUBICIN | HISTONE DEACETYLASE INHIBITOR | PHASE-II TRIAL | LOW-DOSE METHOTREXATE | OF-CANCER EORTC | SEZARY-SYNDROME PATIENTS | PERIPHERAL-BLOOD LYMPHOCYTES | HEMATOLOGY | NF-KAPPA-B | ANTI-CD52 MONOCLONAL-ANTIBODY | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Sezary Syndrome - immunology | Mycosis Fungoides - immunology | Prognosis | Risk Assessment | Humans | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Sezary Syndrome - mortality | Stem Cell Transplantation | Sezary Syndrome - diagnosis | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | T-Lymphocytes - drug effects | Survival Analysis | T-Lymphocytes - immunology | Disease Management | Histone Deacetylase Inhibitors - therapeutic use | Mycosis Fungoides - mortality | Photopheresis | T-Lymphocytes - pathology | Neoplasm Staging | Immunologic Factors - therapeutic use | Mycosis Fungoides - diagnosis | Chemotherapy | Mycoses | Skin | Non-Hodgkin's lymphomas | Diagnosis | T cells | Cancer
PEGYLATED LIPOSOMAL DOXORUBICIN | HISTONE DEACETYLASE INHIBITOR | PHASE-II TRIAL | LOW-DOSE METHOTREXATE | OF-CANCER EORTC | SEZARY-SYNDROME PATIENTS | PERIPHERAL-BLOOD LYMPHOCYTES | HEMATOLOGY | NF-KAPPA-B | ANTI-CD52 MONOCLONAL-ANTIBODY | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Sezary Syndrome - immunology | Mycosis Fungoides - immunology | Prognosis | Risk Assessment | Humans | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Sezary Syndrome - mortality | Stem Cell Transplantation | Sezary Syndrome - diagnosis | Mycosis Fungoides - therapy | Sezary Syndrome - therapy | T-Lymphocytes - drug effects | Survival Analysis | T-Lymphocytes - immunology | Disease Management | Histone Deacetylase Inhibitors - therapeutic use | Mycosis Fungoides - mortality | Photopheresis | T-Lymphocytes - pathology | Neoplasm Staging | Immunologic Factors - therapeutic use | Mycosis Fungoides - diagnosis | Chemotherapy | Mycoses | Skin | Non-Hodgkin's lymphomas | Diagnosis | T cells | Cancer
Journal Article